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Abstract
Background: Selective estrogen receptor modulators (SERMs) have been developed in order to
create means to control estrogenic effects on different tissues. A major drawback in treatment of
estrogen receptor (ER) positive breast cancer with the antagonist tamoxifen (TAM) is its agonistic
effect in the endometrium. Raloxifene (RAL) is the next generation of SERMs where the agonistic
effect on the endometrium has been reduced.
Methods: The aim of the present study was to determine the effect of SERM treatment on the
uterus, as assessed by proliferation markers and several factors involved in uterine growth.
Ovariectomized (ovx) rats were treated with estradiol (E2), tamoxifen (TAM), RAL, ICI182780
(ICI) or vehicle (OVX-controls). We studied the effects on mRNA levels of the growth hormone
(GH) receptor, insulin-like growth factor-I (IGF-I), ERα and ERβ. In addition, by
immunohistochemistry the proliferation markers PCNA and Ki-67, as well as ERα and ERβ, were
detected.
Results: The uterine weight of the rats treated with E2 or TAM was increased as compared to
OVX-controls. The uterine GH-receptor mRNA level was highest in the E2 treated animals. In ICI
treated rats no GH-receptor mRNA could be detected. The IGF-I mRNA level increased 16-fold
in uteri of the TAM treated group and 9-fold in the E2 treated rats as compared to OVX-controls.
The ERα mRNA level was increased in the E2 treated rats, while the ERβ mRNA level was
increased after TAM treatment. The proliferation, as assessed by PCNA, was lowest in ICI treated
animals.
Conclusions: The uterine wet weight, the LE height and the GH-receptor mRNA levels showed
similar patterns, indicating that GH is involved in the regulation of uterine weight. Tamoxifen, which
has been related to increased incidence of endometrial carcinoma in women, dramatically increased
IGF-I mRNA levels in rat uterus. Since proliferation was not higher in TAM and E2 treated rats than
in OVX controls, this assay of simple, early proliferation does not give the full explanation of why
TAM should enhance the risk of developing endometrial cancer.
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Background
In recent years substances being either estrogenic or anti-
estrogenic depending on the tissue where the action is ex-
ercised, the so-called selective estrogen receptor modula-
tors (SERMs), have been developed further [for reviews
see [1–3]]. Tamoxifen (estrogen antagonist in breast, ago-
nist in uterus) is the most commonly used substance for
treatment of women with ER positive breast cancers and
well known to decrease the risk of breast cancer when giv-
en prophylactically [4]. However, the risk of developing
endometrial cancer is increased 3-fold in TAM treated
women [4]. Raloxifene is a representative of the next gen-
eration of SERMs where the agonistic effect on the en-
dometrium has been reduced [4]. ICI182780 is a pure
estrogen receptor antagonist [5], for both ERα and ERβ
[6]. This substance is now also known as fulvestrant
(Faslodex, Astra-Zeneca) [7], and has recently been ap-
proved by FDA in the USA for treatment of hormone-re-
ceptor-positive metastatic breast cancer in post-
menopausal women with the disease progressing follow-
ing anti-estrogen therapy.
In the uterus the proliferative effects of estrogens are me-
diated, at least partly, by growth factors, e.g. IGF-I and ep-
idermal growth factor (EGF) [8–10]. Estrogen treatment
has been shown to increase IGF-I mRNA levels in rodent
uteri [8,9,11]. Treatment of ovariectomized rats with IGF-
I resulted in an increased uterine weight as compared to
controls [11]. Studies in IGF-I knockout mice have shown
that it is not only the locally produced IGF-I that affects
uterine development and epithelial proliferation, the sys-
temic levels of IGF-I are more important than previously
thought [12]. Tamoxifen acts as an estrogen agonist in in-
ducing endometrial expression of IGF-I [13].
GH receptor/GH binding protein immunoreactivity has
been found both in endometrium and myometrium of
rats [14]. In GH receptor/GH binding protein knock-out
mice the GH resistance leads to reduction of peripheral
IGF-I levels. This is associated with delayed puberty of the
females, alterations in fetal and placental growth, delay of
parturition and a reduced litter size [15].
The aim of the present study was to compare effects on
growth promoting factors in the rat uterus after treatment
with estrogen agonists, partial agonists or antagonists.
Treatment with E2, TAM, RAL and ICI are compared. Es-
trogen treatment stimulates uterine proliferation and
thereby increases uterine weight. Several SERMs have been
developed in order to avoid proliferative effects in the
uterus, e.g. RAL. In this study we examined the effects of
these compounds on the mRNA levels of the GH receptor/
GH binding protein, IGF-I, ERα and ERβ in the uteri of
OVX rats. In addition ERα and ERβ were visualized using
immunohistochemistry. The effects on the proliferation
markers PCNA (proliferating cell nuclear antigen) and Ki-
67, as assessed by immunohistochemistry, were also stud-
ied. Ovariectomized animals treated with vehicle alone
served as controls.
Methods
Twenty-seven adult female Sprague-Dawley rats, 55–60
days old and weighing approximately 250 g, were used.
The animals were housed in a controlled environment at
20°C on an illumination schedule of 12 h of light and 12
h of darkness each day. Standard pellet food and water
were provided ad libitum. The rats were anesthetized with
Hypnorm® (fentanyl citrate 0.315 mg/ml + fluanisone 10
mg/ml) (Janssen-Cilag Ltd, Saunderton, UK) and mida-
zolam (Alpharma, Oslo, Norway), ovariectomized and
housed for 14 days before initiation of hormone treat-
ment. They were treated 48 hrs with either 2.5 µg 17β-es-
tradiol (E2) /rat (n = 8) and day, 500 µg tamoxifen (TAM)/
rat (n = 5) and day (both substances purchased from Sig-
ma, St Louis, MO, USA), 500 µg raloxifene (RAL)/rat (n =
5) and day (gift from Eli Lilly and Company, Indianapo-
lis, IN, USA) or 500 µg ICI182780 (ICI)/rat (n = 5) and
day (gift from Dr. A.E. Wakeling). The control group
(OVX) (n = 4) received vehicle only (propylene glycol).
The animals received injections in the morning of day 1
and 2, and were sacrificed in the morning of day 3.
The Committee on Animal Care in Sweden approved the
animal studies.
Tissue collection
During anesthesia, the uterus was removed, stripped of fat
and connective tissue. The uteri were weighed, divided,
one half immediately frozen in liquid nitrogen and stored
at -70°C until analyzed. The other half was immersion-
fixed in 4% formaldehyde at 4°C for 12 hours, stored at
4°C in 70% ethanol and thereafter embedded in paraffin.
Preparation of total nucleic acids
Total nucleic acids (TNA) were prepared as described be-
fore [11]. In short, the tissues were homogenized and di-
gested with proteinase K in a SDS-containing buffer,
followed by subsequent extraction with phenol-chloro-
form as described in [16]. The concentration of total DNA
in the TNA samples was measured fluorometrically at the
wavelength 458 nm with Hoechst Dye 33258 [17].
Solution hybridization analysis of mRNA
The solution hybridization analysis of specific mRNA was
performed as previously described [18,19]. For measure-
ment of mRNA, RNA probes were synthesized in vitro and
radiolabeled with 35S-UTP (Amersham, Bucks, UK). The
in vitro synthesis of radioactive cRNA was performed es-
sentially as described by Melton et al. [20] using reagents
supplied by Promega Biotech, Madison, Wisconsin. 35S-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/40
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UTP cRNA was hybridized (20000 cpm/incubation) at
70°C to TNA samples as previously described [21]. Incu-
bations were performed in micro-centrifuge vials (Treff
AG, Switzerland) in a volume of 40 µl containing 0.6 mol/
l NaCl, 20 mmol/l Tris-HCl, pH 7.5, 4 mmol/l EDTA,
0.1% SDS, 0.75 mmol/l dithiothreitol and 25% forma-
mide. After overnight incubation, samples were treated
with RNase for 45 minutes at 37°C by adding 1 ml of a so-
lution containing 40 µg RNase A and 118 units RNase T1
(Boeringer-Mannheim, Mannheim, Germany) and 100
µg calf thymus DNA to each sample. Radioactivity protect-
ed from RNase digestion was precipitated by the addition
of 100 µl 6 mol/l trichloroacetic acid and collected on a
filter (Whatman GF/C). The radioactivity on the filters
was compared with a standard curve of known amounts
of in vitro synthesized mRNA complementary to the probe
used. Results are expressed as amol (10-18) mRNA/µg
DNA in the TNA sample.
Hybridization probes
The probe used for IGF-I mRNA determinations was de-
rived from a genomic clone of mouse IGF-I [21], a 160 bp
Ban I-Pvu I fragment from exon 3 (assuming homology to
human IGF-I) was subcloned into the RNA expression
vector pSP64. The GH-receptor probe was derived from a
0.6 kb rat GH-receptor cDNA from lambda clone 1 [22].
The probe is directed against the extracellular part of the
receptor and therefore detects also the GH-binding pro-
tein in rodents. Thus, when stated in the following text
that the GH receptor mRNA was measured, it means in
fact a combination of the mRNAs for the GH receptor and
the GH binding protein was assessed. The probe used for
ERα mRNA determinations was derived from pMOR101.
An Eco RI fragment of 1.9 kb containing the whole open
reading frame of the mouse estrogen receptor α [23] was
inserted into a pSP64 vector. Restriction of this plasmid
with Bgl II allows the synthesis of a probe corresponding
to nucleotides 1470–2062, which encode the C-terminal,
half of the steroid binding domain (E) and all of domain
F. The 300 bp probe used for ERβ mRNA determinations
corresponds to an XbaI-EcoRI fragment of the 3' untrans-
lated region, derived from an ERβ clone from rat prostate
(plasmid 37 of clone 29, see ref [24]). It was subcloned
into a Bluescript KS plasmid. After linearization with
XbaI, T3 RNA polymerase was used to transcribe the anti-
sense probe. The sense probe was transcribed from a tem-
plate linearized with Eco RI using T7 polymerase.
Thus, both ERα mRNA and IGF-I mRNA were detected in
the rat tissues using heterologous mouse probes. Rat IGF-
I and mouse IGF-I show a high degree of homology. It is
feasible to use the mouse IGF-I probe to specifically detect
rat IGF-I mRNA as demonstrated by Möller et al. 1991
[25]. The rat ERα mRNA and mouse ERα mRNA show 97
% homology [26] and it has previously been shown that
specific binding is obtained when the mouse ERα probe is
hybridized to rat liver RNA on a Northern blot [18].
Immunohistochemistry
Paraffin sections (5 µm) from the uteri were used. A stand-
ard immunohistochemical technique (avidin-biotin-per-
oxidase) was used to visualize PCNA and Ki-67
immunostaining intensity and distribution. A mouse anti-
PCNA antibody (18–0110; Zymed Laboratories, Inc., San
Francisco, CA) that reacts with PCNA from all vertebrate
species was used in a 1:150 dilution. A monoclonal
mouse anti-human Ki-67 antibody (NCL-Ki67-MM1; No-
vacastra Laboratories Ltd, Newcastle upon Tyne, UK),
which cross-reacts with rat and mouse Ki-67 nuclear anti-
gen was diluted 1:200 and used in the present study. A
monoclonal mouse anti-human antibody was used for
detection of ERα (ZM08-1149, Zymed Laboratories, Inc.,
San Francisco, CA). It recognizes the N-terminal domain
(A/B region) of the ERα, and was diluted 1:15. A polyclo-
nal rabbit anti-rat ERβ antibody (PA1-310B, Affinity Bi-
oreagents, Inc., UK), which corresponds to the C-terminal
amino acid residues 467–485, was used for detection of
the ERβ. It was diluted 1:1000. The immunohistochemis-
try procedure has been described in detail in Wang et al.
1999 [27].
Image analysis
Quantification of PCNA immunostaining was performed
on the digitized images of systematic randomly selected
fields of endometrial stroma, from which non-stromal el-
ements (e.g. luminal and glandular epithelium) were in-
teractively removed, and analyzed separately. A Leica
microscope connected to a computer using Colorvision
software (Leica Imaging System Ltd. Cambridge, England)
was used for the image analysis. All luminal and glandular
epithelia as well as 10 fields of stromal cells were meas-
ured separately in each tissue section. By using color dis-
crimination software, the total area of positively stained
cells (brown reaction product) was measured, and ex-
pressed as a ratio of the total area of cell nuclei (brown re-
action product + blue haematoxylin).
Statistics
The calculation was made by one way ANOVA on ranks
(Kruskal-Wallis test), and significance evaluated by
Dunn's test ("all compared to all" or "all compared to
control"). Values with different letter designations are sig-
nificantly different (p < 0.05). Values with * are signifi-
cantly different (p < 0.05) to OVX control.
Results
The uterine weight of the rats that were treated with E2 or
TAM was increased as compared to the OVX control group
(Fig. 1). The uteri of rats that received RAL or ICI did not
differ in weight compared with OVX controls (Fig. 1). TheReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/40
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effect of estrogen treatment can be assessed from the
height of the luminal and glandular epithelia (LE and GE,
respectively). The results from measuring the LE height in
the slides stained for PCNA is shown (Fig. 1, second row).
The LE height is higher in the E2 and TAM groups as com-
pared to the OVX group (Fig. 1). The E2 treated group is
also different to the ICI treated rats (Fig. 1). The GH-recep-
tor mRNA level was increased in the uteri of the animals
that were treated with E2 as compared to the ICI group
(Fig. 1). In the ICI treated animals no GH-receptor mRNA
could be detected (Fig. 1). The IGF-I mRNA level increased
16-fold in the uteri of the TAM treated group as compared
to OVX controls. The level was higher than in both ICI
treated rats and OVX controls (Fig. 1). The rats that re-
ceived E2 also had an increased level of IGF-I mRNA (9-
fold) as compared to the OVX controls (Fig. 1).
The ERα mRNA level was increased in the E2 treated rats
compared with OVX controls (Fig. 2). Tamoxifen treat-
ment induced an increased ERβ mRNA level compared
with OVX controls (Fig. 2). The ratio of the mRNA levels
of ERα/ERβ was increased in the E2 treated group as com-
pared to TAM and ICI treated rats (Fig. 2).
The distribution of PCNA (A-E) and Ki-67 (G-K) in repre-
sentative slides from the different treatment groups is
Figure 1
The uterine wet weight (g), luminal epithelium (LE) height 
(µm), growth hormone receptor (GH-R) mRNA (amol/µg 
DNA), and insulin-like growth factor-I (IGF-I) mRNA (amol/
µg DNA), in the ovariectomized (OVX) controls and in the 
rats treated with estradiol (E2), tamoxifen (TAM), raloxifene 
(RAL) or ICI182780 (ICI). Box and whisker plots represent-
ing the median value with 50% of all data falling within the 
box. The whiskers extend to the 5th and 95th percentiles. 
Boxes with different letter designations are significantly dif-
ferent (p < 0.05), and the boxes with an * are significantly dif-
ferent to the OVX control group.
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Figure 2
The estrogen receptor α (ERα) mRNA (amol/µg DNA), 
estrogen receptor β (ERβ) mRNA (amol/µg DNA), and the 
ratio of ERα mRNA and ERβ mRNA, in the ovariectomized 
(OVX) controls and in the rats treated with estradiol (E2), 
tamoxifen (TAM), raloxifene (RAL) or ICI182780 (ICI). Box 
and whisker plots representing the median value with 50% of 
all data falling within the box. The whiskers extend to the 5th 
and 95th percentiles. Boxes with different letter designations 
are significantly different (p < 0.05) and the boxes with an * 
are significantly different to the OVX control group.
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shown in Fig. 3. Negative controls where the primary an-
tibody was replaced by IgG were negative for both PCNA
(Fig. 3F) and Ki-67 (Fig. 3L).
PCNA is significantly less expressed in the ICI group, as
compared to the E2, TAM and RAL groups in the stroma
and as compared to the E2 and RAL groups in the GE and
LE (Fig. 4).
The distribution of ERα (A-E) and ERβ (G-K) in represent-
ative slides from the different treatment groups is shown
in Fig. 5. ERα immunostaining is found in the nuclei of
GE and LE, as well as stroma of the uterus (Fig.
5A,5B,5C,5D,5E). The highest intensity of nuclear stain-
ing was observed in the OVX group (Fig. 5A). ERβ immu-
nostaining was found in the nuclei of stroma, LE and GE,
with the highest intensity in the stroma of the E2 and TAM
groups (Fig. 5G,5H,5I,5J,5K). Negative controls where the
primary antibody was replaced by IgG were negative for
both ERα (Fig. 5F) and ERβ (Fig. 5L).
Discussion
The increase in wet weight of the uteri in the treated ani-
mals in this study was as could be expected; i.e. the
weights were in order E2 > or = TAM > or = RAL = ICI =
controls. The uterine GH receptor mRNA level showed a
similar pattern as the weight, although for the GH recep-
tor mRNA there is no significant difference between the
OVX controls and the E2 group (and the E2 and TAM
groups if comparing only to controls). However, the ani-
mals treated with the pure antiestrogen ICI had levels of
GH receptor mRNA below detection limit. This implies
Figure 3
Immunohistochemistry results for PCNA (A-F) and Ki-67 
(G-L). The image of OVX controls (A, G), E2 (B, H), TAM 
(C, I), RAL (D, J) and ICI (E, K) treated rats are shown. 
Negative controls where the primary antibody was replaced 
by IgG are shown for PCNA (F) and Ki-67 (L). The bars rep-
resent 30 µm, all images are in magnification ×200.
Figure 4
Image analysis results of the PCNA immunohistochemistry in 
stroma, glandular epithelium (GE) and luminal epithelium 
(LE). Box and whisker plots representing the median value 
with 50% of all data falling within the box. The whiskers 
extend to the 5th and 95th percentiles. In the control group 
(OVX) and ICI treated group n = 4, in the other groups n = 
5. Values with different letter designations are significantly 
different (p < 0.05).
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that the GH receptor expression could be exclusively reg-
ulated via the estrogen receptors.
The few studies on the GH-receptor expression in the uter-
us found in the literature are contradictory. In one study
GH receptor mRNA was found in the mouse uterus, and
the stromal expression decreased after progesterone treat-
ment but E2 had no regulatory effect [28]. In our experi-
ment the effects of progesterone were not studied. A
reason why E2 was found to regulate GH receptor mRNA
in the present study, as opposed to the study in mice, can
be that we studied effects after a short period of treatment
(48 hrs) while the mice were treated for 8–11 days. It is
possible that the E2  induced increase in GH receptor
mRNA is transient, or E2 has different effects in mice and
rats. In a study on bovines, GH-receptor mRNA was only
found in the pregnant uterus, not in the non-pregnant
[29], while in an immunohistochemistry study on the
non-pregnant rat the GH receptor was found in the uterus
(e.g. in luminal and glandular epithelium, and vascular
endothelium) [14]. In sheep the GH receptor mRNA was
found both in endometrium of cycling and pregnant ani-
mals [30].
In a recent review the importance of GH as a modulator of
female reproduction was discussed [31]. It has been
shown that exogenous GH with the addition of estrogen
promotes proliferation and cellular growth of the rat uter-
us [32,33]. There is a report where GH treatment without
addition of estrogen also stimulates factors that affect
growth of the uterus [34], but other studies disagree with
this [11,33]. Uterine ER mRNA and IGF-I mRNA levels
were not affected by short time (24 hrs) GH treatment in
ovariectomized rats, while E2 in the same regimen caused
increased mRNA levels in both cases [11].
The IGF-I mRNA level was highest in the TAM treated rats,
but the levels in both E2 and TAM treated groups were in-
creased as compared to OVX controls. The high IGF-I
mRNA level could be one explanation for the increased
risk of endometrial carcinoma found in women after TAM
treatment. In TAM treated postmenopausal women the
levels of IGF-I mRNA in the endometrium were shown to
be as high as in type 1 endometrial carcinoma or in nor-
mal endometrium during the secretory and follicular
phases of cycling women [13].
The ERs (both α and β) were expressed in the uteri of the
rats treated with ICI, the ERα mRNA level being similar to
that of the OVX controls and the ERβ mRNA level show-
ing a tendency of increase as compared to OVX controls.
The result on ERα mRNA is in agreement with a previous
study where the ER mRNA levels were shown to be similar
in OVX controls and after ICI or TAM treatment [35]. In
contrast to this are the findings for the ER protein, where
ICI suppressed the levels while TAM had no effect as com-
pared to controls [35]. A possible explanation could be
the fact that ICI, unlike RAL and TAM, decreases the stabil-
ity of the receptor protein [36].
The ratio of ERα/ERβ on the mRNA level seemed to be de-
creased after TAM and ICI treatment, indicating a higher
influence of ERβ. The ERα/ERβ ratio was lower in the TAM
and ICI treated rats as compared to the E2  treated.
Raloxifene showed an intermediate effect on the levels of
ERα and ERβ mRNAs, as well as their ratio, that was not
different from either OVX controls or E2 treated rats.
Ki-67 is expressed in endometrium in all phases of the cell
cycle except G0 [37]. PCNA is found during proliferation
most cell phases [38] and, as opposed to Ki-67, in DNA
Figure 5
Immunohistochemistry results for ERα (A-F) and ERβ (G-
L). The image of OVX controls (A, G), E2 (B, H), TAM (C, 
I), RAL (D, J) and ICI (E, K) treated rats are shown. Nega-
tive controls where the primary antibody was replaced by 
IgG are shown for PCNA (F) and Ki-67 (L). The bars repre-
sent 30 µm, all images are in magnification ×200.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/40
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repair [39]. The results of the immunostaining of prolifer-
ation markers PCNA and Ki-67 were similar. Proliferation
in the uterine tissue was found to be more intense in the
E2, TAM and RAL treated animals, as compared to the
OVX controls and ICI treated rats. Estradiol and TAM
treatment showed similar strong stimulation of LE height,
with active proliferation in GE, LE as well as in the stroma.
RAL treatment has been shown to give less negative side-
effects on the uterus than TAM treatment [4], and this is in
agreement with the low induction of increased LE height
in the present study. Since the proliferation seems as high
in uteri of RAL treated rats as in TAM treated in this study,
the conclusion is that either the proliferation in itself is
not the main cause for developing endometrial carcino-
ma, or the effects on rat tissue is different from that on the
human. Another explanation could be that these markers
are not always specific for cellular proliferation; an in-
crease in their expression may reflect other cellular activi-
ties like DNA repair [39].
Conclusions
The wet weight of the uteri showed a similar pattern as in-
duction of LE height and the GH-receptor mRNA levels,
implicating that GH is involved in the regulation of uter-
ine weight. Tamoxifen, which has been related to in-
creased incidence of endometrial carcinoma in women,
dramatically increased the IGF-I mRNA levels in rat uter-
us. Thus, IGF-I could be a link to the increased risk of de-
veloping endometrial carcinoma, although no firm
conclusion can be drawn between findings in rats and the
outcome of TAM treatment in women. SERMs exhibited
different effects on growth promoting factors and prolifer-
ation that were not obviously correlated to the estrogenic-
ity and/or cancerogenicity attributed to the substance.
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